cawd-176,欧美 性爱 国产 综合,亚洲国产黄色在线,庆余年在线观看免费
中文簡體
中文簡體
English
HOME
ABOUT US
Company Profile
Company Culture
Company Honor
R&D
Technology Platform
Pipelines
NEWS
Press Release
Awards
CAREERS
CONTACT US
中文簡體
中文簡體
English
Search
/uploads/image/img/banner-txt-en-03.svg
首頁
-
NEWS
-
Press Release
Press Release
Awards
Press Release
Awards
Beihai Biotech announced that its innovative cancer drug, BH009 (marketed as BEIZRAY), has received approval from the U.S. Food and Drug Administration (FDA)
2024-10-31
U.S. FDA Formally Accepts Beihai Biotech's New Drug Application for Innovative Oncology Drug BH009 (BEIZRAY?)
2024-01-04
Beihai Biotech Founder Dr. Sun Invited to Keynote 'Wisdom in China' Summit at Renmin University Business School
2023-12-26
Beihai Biotech Successfully Concludes Series C Funding, Expediting BH009 Commercialization and Advancing Clinical Trials for Innovative Drug Candidates
2023-12-19
Beihai Biotech Secures “Drug Manufacturing Certificate”
2023-06-15
Landmark Clinical Research Findings of Beihai Biotech's BH009 Unveiled at ASCO 2023
2023-06-12
貝海生物用于治療晚期三陰性乳腺癌的創(chuàng)新藥物BH009獲批開展II期臨床試驗
2023-04-10
貝海生物BH009新藥項目在晚期頭頸部鱗癌和卵巢癌患者中的I期臨床試驗完成首例患者給藥
2023-03-09
<<
1
2
3
4
>>
ABOUT US
R&D
NEWS
CAREERS
CONTACT US
Contact Information
Company address:Blg 2, No. 6366, Zhuhai Ave., Jinwan, Zhuhai, 519090, China
Tel:0756-6349669
Human resources contact:hr@bayhibiotech.com
Business cooperation contact:hjiang@bayhibiotech.com
Wechat Official Account
Copyright ? 2023 Zhuhai Beihai Biotech Co., Ltd.
Copyright Registration No. :
Guangdong ICP for 17134092
Technical support :
Xiangxun Technology